Table 3.
Currently Open Clinical Trials Investigating BCL2 Family Inhibitors
| Study | Additional Agents | Phase | Patient Population | ||
|---|---|---|---|---|---|
| Lines of Therapy | Cytogenetics | ||||
| Venetoclax | NCT02899052 | Carfilzomib/dex | 2 | ≥1 | t(11;14) |
| NCT03539744 | Venetoclax/dex vs pomalidomide/dex | 3 | ≥2 | t(11;14) | |
| NCT03314181 | Daratumumab/dex ± bortezomib | 1/2 | |||
| AZD5991 | NCT03218683 | 1 | ≥2 | ||
| AMG176 | NCT02675452 | 1 | ≥2 | ||
| AMG397 | NCT03465540 | 1 | |||
| S64315 | NCT02992483 | 1 | ≥1 | ||
| ABBV467 | NCT04178902 | 1 | ≥3 | ||
Abbreviation: Dex, dexamethasone.